Summary: HNF4¡ (encoded by gene NR2A1) is a dominant transcriptional regulator of various drug disposition genes. It forms a circuitry of molecular cross-talk with other nuclear receptors such as PXR and CAR to synergistically initiate transcription. This study reports on the frequency, linkage disequilibrium pattern and tag-SNP selection of NR2A1 polymorphisms in three local Asian populations, namely Chinese, Malays and Indians (n = 56 subjects each). A total of 69 polymorphisms were identified in the genomic region of NR2A1, of which thirty-three were novel polymorphisms with low allelic frequencies (<0.02). The exonic region of NR2A1 was highly conserved with only 4 novel and 1 reported SNPs identified at low allelic frequencies of less than 0.02. Based on the criteria of MAF ² 0.05 and R 2 ² 0.80, there were 19, 20 and 22 tag-SNPs selected to represent the genetic polymorphisms of NR2A1 in Chinese, Malays and Indians, respectively. In-silico predictions suggested that some of these polymorphic variants may exert functional effects through affecting the binding sites of transcription and splicing factors. Our study provides valuable information on the genetic variability of NR2A1 which would be useful for pharmacogenetics studies in the local Asian populations.
Introduction
Hepatocyte nuclear receptor 4 alpha (HNF4¡, encoded by gene NR2A1) is a liver-enriched transcription factor that is also present in the pancreas, kidney, intestine and colon. 1) HNF4¡ is wellknown as the master transcriptional regulator of genes involved in mammalian hepatocyte development and differentiation, as well as glucose and lipid metabolisms. 2, 3) In addition, HNF4¡ also plays a crucial role in xenobiotic detoxifications through modulating the transcriptional activity of the regulatory nuclear receptors such as pregnane X receptor (PXR, encoded by gene NR1I2) and constitutive androstane receptor (CAR, encoded by gene NR1I3). 4) Together, these nuclear receptors form a circuitry of molecular cross-talk with other co-activators to synergistically initiate the transcription of drug disposition genes.
NR2A1 is located on human chromosome 20q13.1-13.2 and it encodes multiple isoforms through two transcription start sites, namely promoter 1 (P1) and promoter 2 (P2), as well as alternative splicing. The usage of the promoter and expression of the isoforms are dependent on the tissue origin, development and differentiation. 5, 6) P2 is located 46 kbp upstream of P1 and is the major transcription site in pancreatic ¢-cells, 7) whereas P1-driven NR2A1 transcripts are predominantly expressed in the liver and kidney. Previously, HNF4¡ was shown to activate transcription and bind to several co-activators in the absence of exogenous ligands. 8) The identification of fatty acid as the endogenous ligand which binds tightly to the HNF4¡ ligand binding domain may explain the constitutive activity of the receptor in regulating transcription. 8, 9) Unlike PXR and CAR, HNF4¡ undergoes homodimerisation instead of heterodimerisation with retinoid X receptor alpha (RXR¡). 10) An HNF4¡ response element has been identified in the pro-moter region of various drug disposition genes such as CYP2A6, CYP2C8, CYP2D6, CYP3A4 and UGT1A9, and site-directed mutations in these sites were demonstrated to lead to significant loss in transcriptional activity in some of the genes. [11] [12] [13] [14] [15] The binding of HNF4¡ to its response element on CYP3A4 was required for basal and PXR/CAR-mediated CYP3A4 promoter activation. 11) Moreover, CYP3A expression was compromised in mice with conditional hepatic deletion of Hnf4¡.
11) Subsequently, Li and Chiang showed that HNF4¡ could potentiate the inductive effect of PXR on CYP3A4 activity despite a site-directed mutation at the HNF4¡ binding site as reported above, indicating that HNF4¡ may act as a co-activator of PXR or CAR through direct binding to them. 16) These findings characterise the mechanistic basis of coregulation between HNF4¡ and other nuclear receptors in gene transcriptional activation.
The role of HNF4¡ in regulating drug disposition genes is further corroborated by a study which demonstrated that NR2A1 knockdown by small interfering RNA in human hepatocytes downregulated the expression of various phase 1 enzymes (CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4), phase 2 enzymes (UGT1A1, UGT1A9, SULT2A1) and transporters (ABCB1, ABCB11, ABCC2, OATP1B1, OCT1). 17) Furthermore, NR2A1 mRNA expression levels were strongly associated with the basal expression levels of the disposition genes mentioned above, highlighting the central role of HNF4¡ as a dominant transcriptional regulator.
18) Interestingly, HNF4¡ is also a positive regulator of the expression of various transcription factors that sequentially control the expression of liver-specific genes, for example NR1I2, NR1I3 and HNF1¡, as well as P450 oxidoreductase (POR), the CYP enzyme electron donor. [18] [19] [20] Genetic alterations in the gene encoding HNF4¡ may contribute to the interindividual differences in the expression or activity of the downstream genes, leading to variability in drug pharmacokinetics and pharmacodynamics. This study reports on the frequency, linkage disequilibrium (LD) pattern and tag-SNP selection of NR2A1 polymorphisms in three local Asian populations, namely Chinese, Malays and Indians.
Methods
Subjects: A total of 168 healthy subjects (Chinese, Malay, Indian, n = 56 per ethnic group) recruited from National University of Singapore participated in this study. The ethnic group of the subjects was confirmed by verbal questioning and verification against their National Registry Identification Cards. This study was approved by the Institutional Review Board of the National University of Singapore. All participants provided written informed consent.
Pharmacogenetics analysis of NR2A1 genetic polymorphisms: Genomic DNA was extracted from the peripheral blood of healthy subjects using ethanol precipitation. The 5A flanking region covering 2.5 kb upstream of 5A untranslated region (UTR), 5A UTR, exons, exon-intron junctions and 3A UTR of NR2A1 (UCSC accession number NM_000457.3; isoform 2) were screened for genetic polymorphisms by direct sequencing using an Applied Biosystems 3730 DNA Analyzer (Applied Biosystems Inc., Foster City, CA, USA).
LD and tag-SNP selection: Chi-square or Fisher's exact test was applied to determine the conformity of genotype distributions to Hardy-Weinberg equilibrium (HWE) and to evaluate the interethnic variability of genotypic frequencies among local Asians. Previously reported data in the Japanese was also included in the interethnic variability comparison. 21 
23)
In-silico prediction of variant function: FastSNP was used to predict the possible regulatory effects (e.g., through affecting splicing and transcription factor binding sites) of polymorphisms located in the 5A flanking region, 5A UTR, exons and introns. 24) The potential function of non-synonymous exonic polymorphisms was also evaluated using SIFT. 25) The 3A UTR of the gene has previously been studied in-silico and in-vitro in relation to microRNA (miRNA) binding. [26] [27] [28] Results and Discussion A total of 69 polymorphisms were identified in the genomic region of NR2A1 (Table 1) , of which 33 were novel polymorphisms with low allelic frequencies of less than 0.02 (information correct as of 14/9/2012; Table 1 ). Among all the SNPs detected, there were thirteen polymorphisms in the 5A flanking region, one in 5A UTR, five in exons, forty in introns and ten in 3A UTR ( Table 1 ). All variations conformed to HWE except for ¹1976A>G (rs2425640) and ¹1975T>C (rs13433202) in the Indian population. Indians harboured a distinct polymorphism profile compared with Chinese and Malays, with significant interethnic differences detected in approximately 25% of the identified polymorphisms ( Table 1) .
A total of 21, 24 and 27 polymorphisms were included in the tag-SNP analyses in Chinese, Malays and Indians, respectively (Fig. 1) . As *906A>C/T (rs3212210) is a triallelic SNP, it was not included in the analysis. Two pairs of SNPs were in high LD (R 2 ² 0.82, «DA« ² 0.95) in all three populations: IVS2¹278A>G (rs55934816) with IVS2¹241C>T (rs6093976) and IVS7¹88T>C (rs2273618) with IVS9¹67C>G (rs3746575). There were 19, 20 and 22 tag-SNPs selected to represent the genetic polymorphisms of NR2A1 in Chinese, Malays and Indians, respectively (Fig. 1) .
The NR2A1 gene was previously screened in a cohort of 74 Japanese type 2 diabetes patients and 39 variations, including 16 novel ones, were identified. 21) A comparative analysis of the aforementioned study with the present data indicated that the majority of the reported polymorphisms were also present at similar frequencies in the local Asian populations, with some exceptions in the Indians ( Table 1) . For example, the allelic frequencies of IVS4+140C>G (rs11574738) and IVS4¹197A>C (rs11574739) were about 0.02 in Chinese, Malays and Japanese, approximately 6-fold lower than the Indian population (0.12). In contrast, the allelic frequencies of IVS5¹136T>C (rs3212200) in Chinese, Malays and Japanese ranged from 0.14 to 0.26, but was rare in Indians (0.01). Interestingly, the rare, novel variant profiles differed greatly across the local Asian and Japanese populations, as exemplified by the unique set of these variants in each population. In particular, three novel exonic SNPs (Ala385Val, Met398Thr and Pro437Pro) which were present in the Japanese population at allelic frequencies of less than 0.01 were absent in our local populations. The great diversity in the rare variant profiles of NR2A1 among the healthy local Asian and Japanese populations suggests the presence of ethnic-specific rare variants.
In the present study, the exonic region of NR2A1 was highly 
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box region and is required for DNA binding and cooperative homodimerisation. 29) This substitution resulted in impaired transcriptional activity in hepatocytes and was shown to be associated with higher risk of type 2 diabetes mellitus. 30) Although both Polyphen and SIFT suggested that this SNP was benign, it was predicted to create an exonic splicing enhancer site as evaluated by FastSNP ( Table 2) . This SNP was present in the heterozygous form in a Chinese and an Indian in the present study. Similarly, this variant was also reported to be rare in the Japanese healthy population with an allelic frequency of less than 0.01. 30) However, it was present at higher frequencies of about 0.05 in the healthy Caucasian populations.
31) The novel exonic variant 505G>A, which causes valine to isoleucine substitution in codon 169 located in the DNA binding domain, was present in one Chinese and two Indian subjects in this study. Although the protein structural change due to the missense variant was predicted to be benign, this SIFT predictions were restricted to non-synonymous coding SNPs.
-: the SNP was not tested using the respective bioinformatics tool as described in footnotes a and b.
variant was predicted to potentially affect the binding of exonic splicing factors (Table 2) . Similarly, the 216C>T (Tyr72Tyr) and 1203C>T (Asn401Asn) polymorphisms were also predicted to influence exonic splicing by FastSNP ( Table 2) . HNF4¡ has been shown to be regulated at the post-transcriptional level by miRNA. 26, 27) The miR-34a and miR-449a were demonstrated to decrease the expression of both the HNF4¡ protein and NR1I2 mRNA. 26) The variant at location *167 (rs11574744; T>A) corresponding to the seed sequence of miR34a and miR-449a was found to abolish the miRNA binding site, and hence alter the mRNA-miRNA interaction in-vitro. 26, 27) This SNP was previously reported to be present in the African American population at an allelic frequency of 3.4% and absent in Asians. 26) Our study did not detect the presence of this variant in the local populations either. However, our populations harbored a common polymorphism *155G>A (rs41280258) which is located 12 bases upstream of rs11574744. This SNP was present at the allelic frequencies of 0.03 in Chinese and Malays, and 0.08 in Indians. Although it does not lie in the seed region of miR-34a and miR449a, it may alter the mRNA-miRNA binding through affecting the interaction of RNA-induced silencing complex (RISC). 32) Another miRNA binding site corresponding to the seed region of the miRNAs mentioned above was predicted at *254_*260 by the same study. 26) Interestingly, this coincides with the location of a novel SNP *256C>T detected in the Indian population at an allelic frequency of 0.01 in our study. The functional consequences of this novel SNP, as well as *155G>A (rs41280258) as mentioned above, remain to be investigated in future studies.
There were a number of other polymorphisms detected in the 5A flanking and intronic regions in the local populations in this study ( Table 1) . Although their in-vitro and in-vivo effects are unknown, in-silico prediction with FastSNP suggested that some of these polymorphic variants may exert functional effects through affecting the binding sites of transcription factors in the promoter or intronic regions ( Table 2) . Five polymorphisms located in the 5A flanking region were predicted to alter the binding of transcription factors, whilst there were 23 intronic variants predicted to affect the functions of intronic enhancers ( Table 2) . Further studies are needed to evaluate their functional relevance.
To date, most studies on the genetic variations of NR2A1 focused on their associations with disease susceptibility, while there is little information available with regard to their roles in drug disposition. HNF4¡ plays a central role in regulating the expression of drug disposition genes, along with PXR and CAR. Our study provides valuable information on the genetic variability of NR2A1 which would be useful for pharmacogenetics studies in the local Asian populations.
